OIRA Conclusion of EO 12866 Regulatory Review
RIN: 0938-AV18 View EO 12866 Meetings | Received Date: 09/26/2023 |
Title: Hospital Outpatient Prospective Payment System: Remedy for 340B-Acquired Drugs Purchased in Cost Years 2018-2022 (CMS-1793) | |
Agency/Subagency: HHS / CMS | Stage: Final Rule |
Concluded Action: Consistent with Change | Concluded Date: 10/31/2023 |
Section 3(f)(1) Significant *: Yes | |
Legal Deadline: Statutory, Judicial | Economically Significant **: No |
Publication Date: 11/08/2023 | Unfunded Mandates: No |
Major: Yes | Related To Homeland Security: No |
Regulatory Flexibility Analysis Required: Yes | Small Entities Affected: Businesses, Governmental Jurisdictions |
Federalism Implications: No | Affordable Care Act [Pub. L. 111-148 & 111-152]: No |
International Impacts: No | Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]: No |
Pandemic Response: No | |
|